Infliximab treatment–induced paradoxical psoriasiform reaction in patient with psoriasis vulgaris showing positive lymphocyte transportation test reaction

نویسندگان

  • Yasue Ishii-Osai
  • Akihiro Yoneta
  • Noriko Mizugaki
  • Hitomi Takahashi
  • Toshiharu Yamashita
چکیده

IFN-a: interferon alfa LTT: lymphocyte transportation test TNF-a: tumor necrosis factorealfa T umor necrosis factor alfa (TNF-a) antagonists are commonly used to treat inflammatory disorders and are considered particularly effective in the treatment of moderate to severe psoriasis. Paradoxically, however, new-onset occurrence orworsening of psoriasis has been increasingly recognized among patients treated with TNF-a antagonists. We report on a 60-year-old man who developed a severe psoriatic condition with diffuse alopecia during infliximab therapy for psoriasis, resulting in the discontinuation of infliximab. Lymphocyte transportation test (LTT) results were positive. Currently, there are few reports of LTTpositive cases that are related to paradoxical reactions by TNF-a antagonists. We discuss the relationship between paradoxical reaction and the mechanisms of LTT.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response

BACKGROUND Tumor necrosis factor-α (TNF-α) inhibitors, such as infliximab, adalimumab, and certolizumab pegol are effective agents in the treatment of inflammatory bowel disease. Some individuals undergoing anti-TNF-α therapy for Crohn's disease or ulcerative colitis develop psoriasiform lesions. This is a paradoxical finding, as classical psoriasis is known to respond to these agents. PURPOS...

متن کامل

Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.

Treatment with antitumor necrosis factor-alpha (anti-TNF-α) offers a significant improvement in several immune-based diseases, including Crohn's disease (CD) and psoriasis. Different cutaneous side effects have been described for anti-TNF-α therapy such as psoriasis. Previous reports showed that inhibition of TNF-α can induce over expression of cutaneous IFN-α, which in turn caused a predisposi...

متن کامل

Clinical management of paradoxical psoriasiform reactions during TNF- α therapy.

There have been reports of paradoxical induction or worsening of psoriasis during treatment with tumor necrosis factor (TNF) α agents (infliximab, etanercept, adalimumab, and certolizumab). It has been hypothesized that an imbalance between TNF-α and interferon α might have a role in the etiology and pathogenesis of these reactions. Paradoxical psoriasiform reactions can be divided clinically i...

متن کامل

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis

OBJECTIVE To assess the efficacy and safety of infliximab for the treatment of psoriasis in a meta-analysis framework. METHODS Data were extracted by searching the EMBASE (1974-2014), PubMed(1966-2014) and the Cochrane library2013.4th databases. Only randomized and placebo-controlled studies were selected in this study. RESULTS Statistically significant differences in efficacy were found fo...

متن کامل

Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis.

Anti-tumour necrosis factor (TNF) agents are attractive approaches to the treatment of auto-inflammatory disorders including psoriasis. Cutaneous side-effects resembling psoriasis or eczema have been reported, with various interpretations concerning a link with a true dermatological disorder, especially psoriasis (1–10). To clarify this issue, we report the detailed investigation of 8 patients ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 1  شماره 

صفحات  -

تاریخ انتشار 2015